Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.

Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST.

Oncotarget. 2017 Sep 30;8(49):86769-86783. doi: 10.18632/oncotarget.21423. eCollection 2017 Oct 17.

2.

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.

Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, Calton CM, Carew JS, Nawrocki ST.

Leukemia. 2018 Jan;32(1):230-233. doi: 10.1038/leu.2017.272. Epub 2017 Aug 23. No abstract available.

3.

Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis.

Carew JS, Espitia CM, Zhao W, Han Y, Visconte V, Phillips J, Nawrocki ST.

Clin Cancer Res. 2017 Jun 1;23(11):2869-2879. doi: 10.1158/1078-0432.CCR-16-1742. Epub 2016 Nov 23.

4.

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.

Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST.

Oncotarget. 2015 Dec 1;6(38):41275-89. doi: 10.18632/oncotarget.5753.

5.

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.

Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A, Advani AS, Maciejewski JP, Sekeres MA, Carew JS.

Leukemia. 2016 May;30(5):1190-4. doi: 10.1038/leu.2015.250. Epub 2015 Sep 15. No abstract available.

6.

Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.

Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST.

Mol Cancer Ther. 2015 Jun;14(6):1404-13. doi: 10.1158/1535-7163.MCT-14-1036. Epub 2015 Mar 25.

7.

Transcriptional profiling of the spleen in progressive visceral leishmaniasis reveals mixed expression of type 1 and type 2 cytokine-responsive genes.

Espitia CM, Saldarriaga OA, Travi BL, Osorio EY, Hernandez A, Band M, Patel MJ, Medina AA, Cappello M, Pekosz A, Melby PC.

BMC Immunol. 2014 Nov 26;15:38. doi: 10.1186/s12865-014-0038-z.

8.

Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.

Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS.

Autophagy. 2014 Aug;10(8):1403-14. doi: 10.4161/auto.29231. Epub 2014 May 20.

9.

Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.

Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, Nawrocki ST.

Cell Death Dis. 2013 Jul 18;4:e728. doi: 10.1038/cddis.2013.259.

10.

Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.

Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A, Carew JS.

Clin Cancer Res. 2013 Jul 1;19(13):3577-90. doi: 10.1158/1078-0432.CCR-12-3212. Epub 2013 Apr 30.

11.

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, Ecsedy J, Giles FJ, Carew JS.

Int J Cancer. 2012 Dec 1;131(11):2693-703. doi: 10.1002/ijc.27579. Epub 2012 Jun 28.

12.

ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.

Carew JS, Esquivel JA 2nd, Espitia CM, Schultes CM, Mülbaier M, Lewis JD, Janssen B, Giles FJ, Nawrocki ST.

PLoS One. 2012;7(1):e31120. doi: 10.1371/journal.pone.0031120. Epub 2012 Jan 25.

13.

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.

Mahalingam D, Espitia CM, Medina EC, Esquivel JA 2nd, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST.

Br J Cancer. 2011 Nov 8;105(10):1563-73. doi: 10.1038/bjc.2011.426. Epub 2011 Oct 20.

14.

Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.

Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, Carew JS, Nawrocki ST.

Oncogene. 2012 Jun 21;31(25):3023-38. doi: 10.1038/onc.2011.478. Epub 2011 Oct 17.

PMID:
22002308
15.

Targeting PIM kinase activity significantly augments the efficacy of cytarabine.

Kelly KR, Espitia CM, Taverna P, Choy G, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS.

Br J Haematol. 2012 Jan;156(1):129-32. doi: 10.1111/j.1365-2141.2011.08792.x. Epub 2011 Jun 21. No abstract available.

PMID:
21689092
16.

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis.

Carew JS, Espitia CM, Esquivel JA 2nd, Mahalingam D, Kelly KR, Reddy G, Giles FJ, Nawrocki ST.

J Biol Chem. 2011 Feb 25;286(8):6602-13. doi: 10.1074/jbc.M110.151324. Epub 2010 Dec 10.

17.

Duplex real-time reverse transcriptase PCR to determine cytokine mRNA expression in a hamster model of New World cutaneous leishmaniasis.

Espitia CM, Zhao W, Saldarriaga O, Osorio Y, Harrison LM, Cappello M, Travi BL, Melby PC.

BMC Immunol. 2010 Jun 22;11:31. doi: 10.1186/1471-2172-11-31.

18.

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST.

Clin Cancer Res. 2010 Jan 1;16(1):141-53. doi: 10.1158/1078-0432.CCR-09-1385. Epub 2009 Dec 22.

Supplemental Content

Loading ...
Support Center